Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the highlights of the abstract regarding patient outcomes associated with cancer-related diarrhea ("CRD") by Napo Pharmaceuticals, Inc. ("Napo"), Jaguar's wholly owned subsidiary, and Napo's collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO®) Annual Meeting, which will be held virtually from June 4-8, 2021. In addition, two CRD-related abstracts from Napo and its collaborators have been accepted for online publication at ASCO.

Jaguar Health and Napo Pharmaceuticals Provide Key Findings from Cancer-related Diarrhea Abstracts Submitted to ASCO for June 2021 Annual Meeting

Newly created Jaguar Health Community Instagram page introduces jaguar-themed contest SAN FRANCISCO, CA / ACCESSWIRE / May 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company recently launched a new social media channel for stakeholders and the Company's growing community of followers. The ‘Jaguar Health Community' Instagram page will serve as a central social media communications hub for all community-building and educational awareness activities.

Jaguar Health Announces the Launch of a New Social Media Channel Dedicated to Reaching the Growing Jaguar Health Community

Canalevia would be first and only FDA-approved plant-based medicine for dogs that suffer from diarrhea during chemotherapy Canalevia will be available by fourth quarter 2021, if conditionally approved SAN FRANCISCO, CA / ACCESSWIRE / May 18, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided updates regarding the development program for the Company's oral plant-based drug candidate Canalevia™ (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea (CID) in dogs and exercise-induced diarrhea (EID) in dogs. There currently is no FDA-approved anti-secretory prescription product to manage these types of debilitating diarrhea in dogs.

Jaguar Health Provides Updates on Canalevia (Crofelemer), the First Plant-based Prescription Medicine Under Development for Chemotherapy-induced Diarrhea in Dogs and Exercise-induced Diarrhea in Dogs

Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q1 2021 Results - Earnings Call Transcript

Shares of Jaguar Health (NASDAQ:JAGX) decreased 1.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 83.93% year over year to ($0.09), which missed the estimate of ($0.02).

Recap: Jaguar Health Q1 Earnings

First quarter 2021 Mytesi gross sales and net sales were approximately $4.6 million and approximately $1.2 million, increases of 250% and 43%, respectively Company to host investor webcast Monday, May 17th at 8:30 a.m. Eastern regarding first quarter 2021 financials & business updates SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated first quarter 2021 financial results.

Jaguar Health, Inc. Reports 2021 First Quarter Financial Results

Based on a preliminary review of votes cast, over 80% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene June 11, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorum Reminder: Jaguar to host investor webcast Monday, May 17th at 8:30 AM Eastern Time regarding Q1 2021 financials & business updates SAN FRANCISCO, CA / ACCESSWIRE / May 14, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that its Annual Meeting of Stockholders held on May 13, 2021 (the "Annual Meeting") was adjourned due to a lack of quorum. The adjourned meeting will be held at 8:30 a.m.

Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, June 11, 2021 and Encourages All Shareholders to Vote

Webcast registration link appears below Company plans to file Q1 2021 10-Q on May 17, 2021 SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a webcast on Monday, May 17, 2021 at 8:30 a.m. Eastern Time to review first-quarter 2021 financials and provide business updates.

Jaguar Health to Host Investor Webcast Monday, May 17th at 8:30 AM Eastern Time Regarding Q1 2021 Financials & Business Updates

American Resources Corp

Cinedigm

Ault Global Holdings

Cenntro Electric Group

Precipio

Support.com

So, which Reddit penny stocks with ambitious plans could pay off down the road? Consider these seven high-risk, high-potential plays as ones where risk/return leans in your favor: The post 7 Reddit Penny Stocks With Interesting Plans appeared first on InvestorPlace.

7 Reddit Penny Stocks With Interesting Plans

Company terminates at-the-market (ATM) financing program SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered into a securities purchase agreement (the "Transaction") with North American institutional investors for the purchase and sale of 7,647,000 shares of common stock for gross proceeds of approximately $10.8 million in a registered direct offering. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent in connection with the Transaction.

Jaguar Health Announces $10.8 Million Registered Direct Offering for the Benefit of Napo EU Business Plan

SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the title of the abstract regarding patient outcomes associated with cancer therapy-related diarrhea ("CTD") by Napo Pharmaceuticals, Inc. ("Napo"), Jaguar's wholly owned subsidiary, and Napo's collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO®) Annual Meeting, which will be held virtually from June 4-8, 2021. The title of the accepted poster presentation is: The impact of cancer-related diarrhea on changes in cancer therapy patterns: Real world evidence Poster Session: Symptoms and Survivorship The lead author of the study is Pablo C.

Jaguar Health and Napo Pharmaceuticals Announce Title of Abstract Regarding Patient Outcomes Associated with Cancer Therapy-Related Diarrhea Accepted for Poster Presentation at the American Society of Clinical Oncology 2021 Annual Meeting

ConforMIS

Zomedica

Creating a penny stock watchlist? You should check these 3 out The post Best Penny Stocks to Buy?

Best Penny Stocks to Buy? You Might Want to Add These 3 To Your Watchlist

Registration link for webcast interview appears below SAN FRANCISCO, CA / ACCESSWIRE / April 21, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued a reminder today about the Innovators with Jane King interview of Lisa Conte, the Company's founder, president, and CEO, and Josh Mailman, the lead sponsor of the Dragon special purpose acquisition company (the "Dragon SPAC"), that will air during a webcast this Friday, April 23, 2021, at 8:30 AM Eastern to provide a business overview of Napo EU S.p.A. ("Napo EU"), Jaguar's wholly owned Italian subsidiary.

REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., Jaguar's New Italian Subsidiary

Registration link for webcast interview appears below Company premiers Napo EU's new logo and branding, now live on Napoeu.com website SAN FRANCISCO, CA / ACCESSWIRE / April 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that an Innovators with Jane King interview of Lisa Conte, the Company's founder, president, and CEO, will be aired during a webcast this Friday, April 23, 2021, at 8:30 AM Eastern to provide a business overview of Napo EU S.p.A. ("Napo EU"), Jaguar's wholly owned Italian subsidiary.

Jaguar Health Announces Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., the Company's New Italian Subsidiary

180 Life Sciences 

Citius Pharmaceuticals

Ocugen, Inc.

Savara

Timber Pharmaceuticals

Zosano Pharma

So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm.

7 Reddit Penny Stocks to Buy for a Biotech Boom

Merger of Napo EU and Dragon SPAC targeted for mid-2021 Jaguar kicks off educational awareness contest in honor of HIV Long-Term Survivors Awareness Day and the 40th anniversary of the first publication defining HIV SAN FRANCISCO, CA / ACCESSWIRE /  April 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced the upsizing by $15.3 million of the at-the-market ("ATM") financing program the Company established on October 5, 2020 with Ladenburg Thalmann & Co. Inc. ("Ladenburg") for potential future financing needs. On April 9, 2021, the Company filed a registration statement and prospectus supplement in connection with its previously disclosed At The Market Offering Agreement with Ladenburg, as agent, to increase the size of the at-the-market offering pursuant to which the Company may offer and sell, from time to time through Ladenburg, shares (the "ATM Shares") of the Company's common stock.

Jaguar Health Announces Upsizing of At-the-Market (ATM) Financing Program by $15.3 Million with Ladenburg Thalmann & Co. Inc. for Potential Future Financing Needs

SAN FRANCISCO, CA / ACCESSWIRE / April 14, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an abstract associated with cancer therapy-related diarrhea ("CTD") by Napo Pharmaceuticals, Inc. ("Napo"), Jaguar's wholly owned subsidiary, and Napo's collaborators has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO®) Annual Meeting, which will be held virtually from June 4-8, 2021. Two other CTD-related abstracts from Napo and its collaborators have also been accepted for online publication for the 2021 ASCO Annual Meeting.

Jaguar Health and Napo Pharmaceuticals Announce Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Annual Meeting

Stock purchase price under the agreement increases to $3.00 per share SAN FRANCISCO, CA / ACCESSWIRE / April 8, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar has entered into an amendment (the "Amendment") to the March 24, 2020 equity purchase agreement (the "Equity Purchase Agreement") with Oasis Capital, LLC ("Oasis Capital"). As previously announced, Oasis is committed to purchasing up to an aggregate of $2.0 million of Jaguar common stock over the 36-month term of the Equity Purchase Agreement.

Jaguar Health Announces Amendment to March 2020 Equity Purchase Agreement with Oasis Capital, LLC

SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company has promoted Carol Lizak, an accomplished financial executive, to the expanded role of chief financial officer. "We are thrilled to have Carol take on this important and expanded role as part of Jaguar's management team.

Jaguar Health Promotes Carol Lizak to Chief Financial Officer

It's easy to dismiss JAGX stock as just another beneficiary of the equity bull market. However, Jaguar Health has made significant strides during the last year.

Jaguar Health Has Enough Short-Term Catalysts To Make It Interesting

Jaguar Health (JAGX) stock is heading higher on Thursday following the release of the biopharma company's earnings for the full year of 2020. The post JAGX Stock: 15 Things Giving Jaguar Health Shares a Jolt Today appeared first on InvestorPlace.

JAGX Stock: 15 Things Giving Jaguar Health Shares a Jolt Today

The stock price of Jaguar Health, Inc. (NASDAQ:JAGX) increased by over 10% pre-market. This is why it happened.

JAGX Stock Price Increased Over 10% Pre-Market: Why It Happened

Mytesi® net sales and gross sales grew 64% and 148%, respectively, in 2020 compared to 2019 SAN FRANCISCO, CA / ACCESSWIRE / March 31, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2020. 2020 Company Financial Results: Mytesi® Net Product Revenue: 2020 Mytesi net sales were approximately $9.3 million, and Mytesi gross (non-GAAP) sales were approximately $20.4 million, an increase of 64% and 148%, respectively, year over year.

Jaguar Health Reports 2020 Financial Results and Business Updates

Update regarding March 15, 2021 meeting with European regulatory authority regarding potential Covid-related indication for crofelemer SAN FRANCISCO, CA / ACCESSWIRE / March 30, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company supports the selection of the investment bank and nominated advisor ("NOMAD") made by the lead sponsor of the planned Dragon special purpose acquisition company (the "Dragon SPAC"). The Dragon SPAC anticipates listing on AIM Italia and merging with its named target, Napo EU S.p.A.

Jaguar Health Announces Selection of Investment Bank and Nominated Advisor for Proposed Merger of the Dragon SPAC and Napo EU, Jaguar's Italian Subsidiary

New educational contest to begin in April in honor of HIV Long-Term Survivors Awareness Day and the 40th anniversary of the first publication defining HIV SAN FRANCISCO, CA / ACCESSWIRE / March 22, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that Maribel P.L., a nurse from New York, is the winner of the Company's International Day of Forests educational awareness contest.

News for Jaguar Health Stock (JAGX)